{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T13:29:14Z","timestamp":1790515754857,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T00:00:00Z","timestamp":1467849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>In vitro<\/jats:italic> amplification assays, such as real-time quaking-induced conversion (RT-QuIC) are used to detect aggregation activity of misfolded prion protein (PrP) in brain, cerebrospinal fluid (CSF) and urine samples from patients with a prion disease. We believe that the method also has a much broader application spectrum. In the present study, we applied RT-QuIC as a pre-screening test for substances that potentially inhibit the aggregation process of the cellular PrP (PrP<jats:sup>C<\/jats:sup>) to proteinase (PK)-resistant PrP<jats:sup>res<\/jats:sup>. We chose doxycycline as the test substance as it has been tested successfully in animal models and proposed in clinical studies as a therapeutic for prion diseases. The RT-QuIC-reaction was seeded with brain tissue or CSF from sCJD patients and doxycycline was then added in different concentrations as well as at different time points. In both experiments, we observed a dose- and time-dependent inhibition of the RT-QuIC seeding response and a decrease of PK resistant PrP<jats:sup>res<\/jats:sup> when doxycycline was added. In contrast, ampicillin or sucrose had no effect on the RT-QuIC seeding response. Our study is the first to apply RT-QuIC as a pre-screening assay for compounds inhibiting the PrP aggregation <jats:italic>in vitro<\/jats:italic> and confirms that doxycycline is an efficient inhibitor of the PrP aggregation process in RT-QuIC analysis.<\/jats:p>","DOI":"10.1038\/srep28711","type":"journal-article","created":{"date-parts":[[2016,7,7]],"date-time":"2016-07-07T09:35:18Z","timestamp":1467884118000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie"],"prefix":"10.1038","volume":"6","author":[{"given":"Matthias","family":"Schmitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Cramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franc","family":"Llorens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccol\u00f2","family":"Candelise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"M\u00fcller-Cramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Varges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter J.","family":"Schulz-Schaeffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saima","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inga","family":"Zerr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,7]]},"reference":[{"key":"BFsrep28711_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1126\/science.6801762","volume":"216","author":"SB Prusiner","year":"1982","unstructured":"Prusiner, S. B. Novel proteinaceous infectious particles cause scrapie. Science 216, 136\u2013144 (1982).","journal-title":"Science"},{"key":"BFsrep28711_CR2","doi-asserted-by":"publisher","first-page":"e1001217","DOI":"10.1371\/journal.ppat.1001217","volume":"6","author":"JM Wilham","year":"2010","unstructured":"Wilham, J. M. et al. Rapid end-point quantitation of prion seeding activity with sensitivity comparable to bioassays. PLoS Pathog 6, e1001217 (2010).","journal-title":"PLoS Pathog"},{"key":"BFsrep28711_CR3","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1099\/vir.0.033365-0","volume":"93","author":"AH Peden","year":"2012","unstructured":"Peden, A. H. et al. Sensitive and specific detection of sporadic Creutzfeldt-Jakob disease brain prion protein using real-time quaking-induced conversion. J Gen Virol 93, 438\u201349 (2012).","journal-title":"J Gen Virol"},{"key":"BFsrep28711_CR4","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/nm.2294","volume":"17","author":"R Atarashi","year":"2011","unstructured":"Atarashi, R. et al. Ultrasensitive human prion detection in cerebrospinal fluid by real-time quaking-induced conversion. Nat Med 17, 175-8 (2011).","journal-title":"Nat Med"},{"key":"BFsrep28711_CR5","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1002\/ana.23589","volume":"72","author":"LI McGuire","year":"2012","unstructured":"McGuire, L. I. et al. Real time quaking-induced conversion analysis of cerebrospinal fluid in sporadic Creutzfeldt-Jakob disease. Ann Neurol 72, 278\u201385 (2012).","journal-title":"Ann Neurol"},{"key":"BFsrep28711_CR6","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1007\/s12035-015-9133-2","volume":"53","author":"M Cramm","year":"2016","unstructured":"Cramm, M. et al. Stability and reproducibility underscore utility of RT-QuIC for diagnosis of Creutzfeldt-Jakob disease. Mol Neurobiol 53, 1896\u2013904 (2016).","journal-title":"Mol Neurobiol"},{"key":"BFsrep28711_CR7","doi-asserted-by":"publisher","first-page":"e54915","DOI":"10.1371\/journal.pone.0054915","volume":"8","author":"K Sano","year":"2013","unstructured":"Sano, K. et al. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS ONE 8, e54915 (2013).","journal-title":"PLoS ONE"},{"key":"BFsrep28711_CR8","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1007\/s12035-014-8709-6","volume":"51","author":"M Cramm","year":"2015","unstructured":"Cramm, M. et al. Characteristic CSF prion-seeding efficiency in humans with prion diseases. Mol Neurobiol 51, 396\u2013405 (2015).","journal-title":"Mol Neurobiol"},{"key":"BFsrep28711_CR9","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1073\/pnas.162195499","volume":"99","author":"G Forloni","year":"2002","unstructured":"Forloni, G. et al. Tetracyclines affect prion infectivity. Proc Natl Acad Sci 99, 10849\u201354 (2002).","journal-title":"Proc Natl Acad Sci"},{"key":"BFsrep28711_CR10","doi-asserted-by":"publisher","first-page":"e1888","DOI":"10.1371\/journal.pone.0001888","volume":"3","author":"A De Luigi","year":"2008","unstructured":"De Luigi, A. et al. The efficacy of tetracyclines in peripheral and intracerebral prion infection. PLoS ONE 3, e1888 (2008).","journal-title":"PLoS ONE"},{"key":"BFsrep28711_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.2174\/1871526510909010092","volume":"1","author":"I Zerr","year":"2009","unstructured":"Zerr, I. Therapeutic trails in human transmissible spongiform encephalopaths: recent advances and problems to address. Infect Disord Drug Targets 1, 92\u201399 (2009).","journal-title":"Infect Disord Drug Targets"},{"key":"BFsrep28711_CR12","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk, S. et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol 13, 150\u20138 (2014).","journal-title":"Lancet Neurol"},{"key":"BFsrep28711_CR13","doi-asserted-by":"publisher","first-page":"e00078","DOI":"10.1128\/mBio.00078-11","volume":"2","author":"CD Orr\u00fa","year":"2011","unstructured":"Orr\u00fa, C. D. et al. Prion disease blood test using immunoprecipitation and improved quaking induced conversion. MBio 2, e00078\u201311 (2011).","journal-title":"MBio"},{"key":"BFsrep28711_CR14","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1097\/NEN.0b013e31829d2799","volume":"72","author":"WE Wemheuer","year":"2013","unstructured":"Wemheuer, W. E., Wrede, A., Gawinecka, J., Zerr, I. & Schulz-Schaeffer, W. Filtration of protein aggregates increases the accuracy for diagnosing prion diseases in brain biopsies. J Neuropathol Exp Neurol 72, 758\u201367 (2013).","journal-title":"J Neuropathol Exp Neurol"},{"key":"BFsrep28711_CR15","doi-asserted-by":"publisher","first-page":"e1004983","DOI":"10.1371\/journal.ppat.1004983","volume":"11","author":"CD Orr\u00fa","year":"2015","unstructured":"Orr\u00fa, C. D. et al. Bank vole prion protein as an apparently universal substrate for RT-QuIC-based detection and discrimination of prion strains. PLoS Pathog 11, e1004983 (2015).","journal-title":"PLoS Pathog"},{"key":"BFsrep28711_CR16","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.neurobiolaging.2013.11.010","volume":"35","author":"M Schmitz","year":"2014","unstructured":"Schmitz, M. et al. Association of prion protein genotype and scrapie prion protein type with cellular prion protein charge isoform profiles in cerebrospinal fluid of humans with sporadic of familial prion diseases. Neurobiol Aging 35, 1177\u201388 (2014).","journal-title":"Neurobiol Aging"},{"key":"BFsrep28711_CR17","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.saa.2009.05.010","volume":"74","author":"P Sen","year":"2009","unstructured":"Sen, P., Fatima, S., Ahmad, B. & Khan, R. H. Interactions of thioflavin T with serum albumins: Spectroscopic analyses. Spectrochimica Acta Part A 74, 94\u201399 (2009).","journal-title":"Spectrochimica Acta Part A"},{"key":"BFsrep28711_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1002\/ana.10336","volume":"52","author":"SJ Collins","year":"2002","unstructured":"Collins, S. J. et al. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol 52, 503\u20136 (2002).","journal-title":"Ann Neurol"},{"key":"BFsrep28711_CR19","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1111\/j.1468-1331.2008.02108.x","volume":"15","author":"I Bone","year":"2008","unstructured":"Bone, I., Belton, L., Walker, A. S. & Darbyshire, J. Intraventricular pentosan polysulphate in human prion diseases: an observational study in the UK. Eur J Neurol 15, 458\u201364 (2008).","journal-title":"Eur J Neurol"},{"key":"BFsrep28711_CR20","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/S0014-5793(00)02380-2","volume":"487","author":"G Forloni","year":"2001","unstructured":"Forloni, G., Colombo, L., Girola, L., Tagliavini, F. & Salmona, M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett 487, 404\u20137 (2001).","journal-title":"FEBS Lett"},{"key":"BFsrep28711_CR21","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00894-008-0348-2","volume":"14","author":"U Cosentino","year":"2008","unstructured":"Cosentino, U. et al. The anti-fibrillogenic activity of tetracyclines on PrP 106-126: a 3D-QSAR study. J Mol Model 14, 987\u201394 (2008).","journal-title":"J Mol Model"},{"key":"BFsrep28711_CR22","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1128\/AAC.40.5.1104","volume":"40","author":"M Karlsson","year":"1996","unstructured":"Karlsson, M., Hammers, S., Nilsson-Ehle, I., Malmborg, A. S. & Wretlind, B. Concentrations of doxycycline and penicillin G in sera and cerebrospinal fluid of patients treated for neuroborreliosis. Antimicrob Agents Chemother 40, 1104\u20137 (1996).","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep28711","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep28711.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T16:23:12Z","timestamp":1672849392000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep28711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,7]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,9,1]]}},"alternative-id":["BFsrep28711"],"URL":"https:\/\/doi.org\/10.1038\/srep28711","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,7]]},"assertion":[{"value":"20 November 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"28711"}}